ArticleARYA atherosclerosis2026
Retrograde transcatheter closure of perimembranous and muscular ventricular septal defects in pediatric and adult patients: 12month outcomes in a case series of 60 patients from Iran.
Article in ARYA atherosclerosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConventional antegrade transcatheter closure of ventricular septal defects (VSDs) requires prolonged fluoroscopy and risks right-heart complications. This study evaluated the safety, efficacy, and 12-month outcomes of the retrograde approach using direct left ventricular access in pediatric and adult patients.
methodsBetween January 2022 and June 2024, 60 consecutive Iranian patients (median age 10 years, range 1-40 years) with perimembranous (n = 48) or muscular (n = 12) VSDs underwent retrograde transcatheter closure using LifeTech occluders via bilateral femoral arterial access and left-sided transthoracic echocardiography at two centers in Kerman, Iran.
resultsTechnical success was 100%, with 95% achieved on the first attempt. Median defect size was 6.2 mm (range 2.8-11 mm). The Qp/Qs ratio decreased from 2.2 ± 0.5 to 1.1 ± 0.2 (P < 0.001), and ejection fraction increased from 58.5 ± 7.2% to 62.2 ± 6.5% (P < 0.05). Mean fluoroscopy time was 13.3 ± 4.1 minutes, radiation dose was 2.8 ± 1.1 mGy, and hospital stay was 1.2 ± 0.5 days. Minor complications occurred in five patients (8.3%; all Clavien-Dindo Grade I) and resolved without sequelae. At 12-month follow-up with cardiac CT or MRI in all patients, no device migration, embolization, aortic erosion, or significant residual shunt was observed.
conclusionRetrograde transcatheter VSD closure appears to be safe and effective, and it may be reducing radiation exposure safe and highly effective, significantly reducing radiation exposure, making it a potential attractive alternative to conventional techniques in children and pediatric and adult patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.